Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is AMGN's Other Investing Activities?

  Amgen Inc ( AMGN ) |
1989 - 2021 (33 years)

Other Investing Activities is 
$95.2M (1Y +39.0% )

AMGN Stock Price & Other Investing Activities

Other Investing Activities for AMGN competitors.
ALXN CELG GILD BIIB GSK BMY JNJ PFE ABBV
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Other Investing Activities

chevron_right 2021 $41.0M +24.6x *
( +10.3% / year avg)
chevron_left 1989 -$1.6M
vertical_align_top Peak $672.6M +2.52x *
vertical_align_bottom Bottom -$443.0M
arrow_drop_up # Up Years 8 8 of 33
years up.
arrow_drop_down # Down Years 25
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • AMGN's stock price has rallied +113,400% from $0.22 in 1989 , or -42.6x faster than it's other investing activities over the same period.
  • If AMGN grows it's stock at the same rate as it's other investing activities (+10.3%/year) , it's stock price will grow +266% and hit $657.68 over the next 10 years.
  • AMGN's stock price has gone up 4 of the 8 years (+50%) it's other investing activities were also up.
* A modified method (see: here) is used to calculate changes that involve negative numbers.
  • AMGN Historical Other Investing Activities Table
    in $ million
    * A modified method (see: here) is used to calculate changes that involve negative numbers.
    Year Other Investing Activities YoY % Change* Stock Price YoY % Change (Stock Price)
    4/1/2021 $41 -193.2% $246.75 0.0%
    4/1/2020 $-44 -118.9% $246.75 7.3%
    4/1/2019 $233 156.0% $229.96 16.1%
    4/1/2018 $91 15.2% $198.0 22.0%
    4/1/2017 $79 -81.0% $162.25 25.3%
    4/1/2016 $415 10.1% $129.45 -8.2%
    4/1/2015 $377 -185.1% $141.03 -0.6%
    4/1/2014 $-443 -181.7% $141.87 47.7%
    4/1/2013 $542 -385.5% $96.04 30.8%
    4/1/2012 $-190 -2475.0% $73.4 56.3%
    4/1/2011 $8 -88.4% $46.96 11.0%
    4/1/2010 $69 -185.2% $42.29 -6.5%
    4/1/2009 $-81 -47.4% $45.23 1.5%
    4/1/2008 $-154 -238.7% $44.58 0.5%
    4/1/2007 $111 -43.1% $44.34 -22.2%
    4/1/2006 $195 -523.9% $57.02 -12.2%
    4/1/2005 $-46 -137.3% $64.96 34.8%
    4/1/2004 $123 -81.7% $48.19 4.2%
    4/1/2003 $672 -341.3% $46.25 22.1%
    4/1/2002 $-278 1796.3% $37.88 -28.9%
    4/1/2001 $-14 -198.0% $53.32 4.4%
    4/1/2000 $15 837.5% $51.07 39.6%
    4/1/1999 $1 -94.0% $36.57 142.2%
    4/1/1998 $26 -52.6% $15.1 47.2%
    4/1/1997 $56 -39.4% $10.26 -16.0%
    4/1/1996 $93 -64.6% $12.21 22.7%
    4/1/1995 $262 2663.2% $9.96 70.0%
    4/1/1994 $9 -80.5% $5.86 27.9%
    4/1/1993 $48 532.5% $4.58 -31.6%
    4/1/1992 $7 -254.0% $6.7 11.3%
    4/1/1991 $-5 -133.3% $6.02 317.4%
    4/1/1990 $15 -1037.5% $1.44 98.3%
    4/1/1989 $-1 - $0.73 -

  • About
    Industry: Drug Manufacturers General
    Sector: Healthcare
    Country: US
    IPO Date: 5/1/1987
    Stonk Exchange: NASDAQ
    • Amgen, Inc
    • is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics.
    • The company is headquartered in Thousand Oaks, California and currently employs 21,500 full-time employees.
    • The firm discovers, develops, manufactures and delivers various human therapeutics.
    • The company operates in human therapeutics segment.
    • Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
    • The company focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience.
    • Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

  • Cash flows from investing activities (CIA) provides an account of cash used in the purchase of non-current assets–or long-term assets– that will deliver value in the future.

    Other investing activities are investing activities that are not specified in the financial statement.

    Other financing activities are non-cash items that are not specified in the CIA section of the Cash Flow Statement.

    For more detailed definitions, please see Investopedia.